ERBB2 and breast carcinoma: Several trials have studied the efficacy of trastuzumab in early-stage HER2-positive breast cancer, and have shown benefits in disease-free and overall survival, with ~50% reduction in disease recurrence (B31/N9831, BCIRG006, FinHER and HERA) (10–13).